Moderna Corporation revealed that it is developing a single-dose vaccine that combines the booster vaccines for the Corona virus and influenza, explaining that the vaccine mRNA-1073It will be a combination of Moderna’s vaccine against Corona, and the influenza vaccine that the company is developing, according to the British newspaper, Daily Mail.
Moderna finds a vaccine that combines a mixture of corona and influenza
The newspaper indicated that there are no known details about when the clinical trials will start or when the vaccine will be available to the general public, and this comes one day after Novavax announced NovavaxIt has begun an early-stage study to test the combined influenza and corona vaccine.
Moderna Corporation announced Modern Recently it is developing a single-dose vaccine that combines a booster dose against the coronavirus and a booster against influenza. mRNA-1073, a combination of the company’s corona vaccine with the flu vaccine being developed by Moderna Modern
“Today we are announcing the first step in our new respiratory vaccine program with the development of a single-dose vaccine that combines a coronavirus booster and an influenza booster,” said Stéphane Bancel, Moderna CEO, in a statement.“.
“We are making progress in enrolling patients in our rare disease programs, and we are fully enrolled in our custom cancer vaccine trial,” he said. The vaccine will be available to the general public.
Moderna Vaccine Booster Doses
became a modern company Modern, a household name when it became the second company to obtain emergency approval for the Corona vaccine in December 2020 for those aged 18 and over, as it is one of the first vaccines in the world, along with the Pfizer vaccine. Pfizer-BioNTech Covid –who uses technology messenger RNA new (mRNA)This technology works by using part of the genetic code of the Corona virus to trick the body into producing a harmless part of the virus, and this makes the body recognize the invader and launch an immune response by making customized proteins ready to attack in the event a person becomes infected..
This comes after Novafax said Novavax On Wednesday, it began an early-stage study to test the combined flu and corona vaccine, in which participants will receive a mixture of the company’s candidate corona vaccine, NVX-CoV2373 flu vaccine, NanoFlu Combined with an adjuvant or a booster vaccine, which has provoked NanoFlu / NVX-CoV2373 Strong responses to both influenza” A And B “, and its protection from the Corona virus in preclinical studies.
The newspaper pointed out, Moderna company has presented Modern Also Thursday updates on its ongoing trial to test the coronavirus vaccine in children aged 6 months and under 12 years old..
The company’s vaccine, which received emergency clearance for people 18 and older in the United States last December, is currently under FDA review for use in people ages 12 to 17..
As part of the pediatric trial, the company said it will test 50 micrograms of its vaccine in a study group of 4,000 children ages 6 to under 12..
Moderna said studies of dose selection for different age groups, such as 6 years to less than 6 years, and 6 months to less than 2 years, are still ongoing..
“I am proud of the progress the Moderna team has made in developing the mRNA pipeline,” Bancel said in his statement mRNABest in class while tackling the Corona pandemic, adding, “We believe that the . platform mRNA Our own can solve the world’s biggest health challenges, from diseases that affect millions, to very rare diseases that affect dozens.